BioInsights - Key considerations for early investment in the process development of cell-based therapeutics

Key considerations for early investment in the process development of cell-based therapeutics

Cell & Gene Therapy Insights 2022; 8(10), 1407–1412

DOI: 10.18609/cgti.2022.206

Published: 23 November 2022
Viewpoint
Kelly Kemp, Sebastian Rieck



“During early process development, every relevant aspect of a product’s lifecycle and cost-of-goods should be taken into consideration.”


On October 3, 2022, David McCall, Commissioning Editor, Cell & Gene Therapy Insights, spoke to Kelly Kemp (left) and Sebastian Rieck (right) about current challenges in cell therapy process development and manufacture. This viewpoint has been written based on that interview.